Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2026)
Bicycle Therapeutics posted quarterly Other Non-Current Liabilities of $973000.0 for Q1 2026, down 12.81% year-on-year from $1.1 million in Q1 2025, and down 5.72% on a QoQ basis from $1.0 million in Q4 2025.
Bicycle Therapeutics (BCYC) has 9 years of Other Non-Current Liabilities data on file, last reported at $973000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 12.81% year-over-year to $973000.0; the trailing twelve-month figure through Mar 2026 stood at $973000.0 (down 12.81% YoY), and the FY2025 full-year result was $1.0 million, down 7.94% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $973000.0, down from $1.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.0 million in Q3 2024 and bottomed at $973000.0 in Q1 2026.
- The 5-year median for Other Non-Current Liabilities is $3.4 million (2022), against an average of $3.1 million.
- The widest annual swing landed in 2024, when Other Non-Current Liabilities soared 38.16%; it then slumped 81.67% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $3.8 million in 2022, then advanced by 19.59% to $4.6 million in 2023, then slumped by 75.52% to $1.1 million in 2024, then decreased by 7.94% to $1.0 million in 2025, then declined by 5.72% to $973000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $973000.0 (Q1 2026), $1.0 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 973,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 4.58 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 3.83 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 3.26 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 3.28 Mn |
| Sep 30, 2021 | 3.04 Mn |
| Jun 30, 2021 | 2.96 Mn |
| Mar 31, 2021 | 2.81 Mn |
| Dec 31, 2020 | 2.61 Mn |
| Sep 30, 2020 | 2.31 Mn |
| Jun 30, 2020 | 2.09 Mn |
| Mar 31, 2020 | 2.01 Mn |
| Dec 31, 2019 | 2.00 Mn |
| Sep 30, 2019 | 1.43 Mn |
| Jun 30, 2019 | 1.26 Mn |
| Dec 31, 2018 | 897,000.00 |